1 / 47

CHAPTER 12 Peritoneal Dialysis

CHAPTER 12 Peritoneal Dialysis. Lily Mushahar Sunita Bavanandan Anita Bhajan Manocha. Source: 21 st MDTR Report 2013, NRR. Table 12.1.1: Peritoneal dialysis regimes, 2004-2013. Source: 21 st MDTR Report 2013, NRR. Table 12.1.2: CAPD connectology, 2004-2013.

gracie
Télécharger la présentation

CHAPTER 12 Peritoneal Dialysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CHAPTER 12Peritoneal Dialysis Lily Mushahar Sunita Bavanandan Anita Bhajan Manocha Source: 21st MDTR Report 2013, NRR

  2. Table 12.1.1: Peritoneal dialysis regimes, 2004-2013 Source: 21st MDTR Report 2013, NRR

  3. Table 12.1.2: CAPD connectology, 2004-2013 Source: 21st MDTR Report 2013, NRR

  4. Table 12.1.3(a): CAPD Number of Exchanges per day, 2004-2013 Source: 21st MDTR Report 2013, NRR

  5. Table 12.1.3(b): APD dwell volumes per day, 2004-2013 Source: 21st MDTR Report 2013, NRR

  6. Table 12.1.4: Assistance to Perform PD, 2004-2013 Source: 21st MDTR Report 2013, NRR

  7. Figure 12.1.4(a): Assistance to Perform CAPD, 2004-2013 Self-care Partial Self-care completely assisted Unknown 100 80 60 Percent (%) 40 20 0 2007 2008 2009 2010 2011 2006 2013 2004 2005 2012 CAPD Source: 21st MDTR Report 2013, NRR

  8. Figure 12.1.4(b): Assistance to Perform APD, 2004-2013 Self-care Partial Self-care completely assisted Unknown 100 80 60 Percent (%) 40 20 0 2006 2007 2008 2009 2010 2011 2013 2004 2005 2012 APD Source: 21st MDTR Report 2013, NRR

  9. Table 12.2.1: Distribution of delivered Kt/V, PD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

  10. Figure 12.2.1: Cumulative distribution of delivered Kt/V, PD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

  11. Table 12.2.2: Variation in proportion of patients with Kt/V 1.7 per week among PD centres, 2004-2013 Source: 21st MDTR Report 2013, NRR

  12. Figure 12.2.2: Variation in proportion of patients with Kt/V 1.7 per week among PD centres 2013 % with KT/V >=1.7 per week (lower 95% CI, upper 95% CI) 100 90 80 70 60 % patients 50 40 30 20 10 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Centre Source: 21st MDTR Report 2013, NRR

  13. Table 12.2.3: Peritoneal transport status by PET D/P creatinine at 4 hours, new PD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

  14. Table 12.2.4: Peritoneal Transport Status (PET) with dialysis vintage Source: 21st MDTR Report 2013, NRR

  15. Table 12.2.5: Residual Urine Volume Source: 21st MDTR Report 2013, NRR

  16. Figure 12.2.5: Residual Urine Volume in prevalent PD patients (2013) <100 mls 100-<400 mls 400-<800 mls 800-<1000 mls >=1000 mls 100 80 60 Percent (%) 40 20 0 <1 1-<2 2-<4 >=4 Duration(Years) Source: 21st MDTR Report 2013, NRR

  17. Table 12.3.1(a): Unadjusted technique survival by era 2004–2008 and 2009–2013 (uncensored for death and transplant) Source: 21st MDTR Report 2013, NRR

  18. Figure 12.3.1(a): Unadjusted technique survival by era 2004–2008 and 2009–2013 (uncensored for death and transplant) Kaplan-Meier survival estimates, by Era 1.00 0.75 Cumulative survival 0.50 Year 2009-2013 0.25 Year 2004-2008 0.00 0 12 24 36 48 60 72 84 96 108 120 Duration in months Source: 21st MDTR Report 2013, NRR

  19. Table 12.3.1(b): Unadjusted technique survival by era 2004–2008 and 2009–2013 (censored for death and transplant) Source: 21st MDTR Report 2013, NRR

  20. Figure 12.3.1(b): Unadjusted technique survival by era 2004–2008 and 2009–2013 (censored for death and transplant) Kaplan-Meier survival estimates, by Era 1.00 0.75 Year 2009-2013 Year 2004-2008 Cumulative survival 0.50 0.25 0.00 0 12 24 36 48 60 72 84 96 108 120 Duration in months Source: 21st MDTR Report 2013, NRR

  21. Table 12.3.2(a): Unadjusted technique survival by age (uncensored for death and transplant), 2004-2013 Source: 21st MDTR Report 2013, NRR

  22. Figure 12.3.2(a): Unadjusted technique survival by age (uncensored for death and transplant), 2004-2013 Kaplan-Meier survival estimates, by Age 1.00 0.80 0.60 Cumulative survival 0.40 Age 1-14 Age 15-24 0.20 Age 25-34 Age 35-44 Age 45-54 Age 55-64 Age>=65 0.00 0 12 24 36 48 60 72 84 96 108 120 132 144 Duration in months Source: 21st MDTR Report 2013, NRR

  23. Table 12.3.2(b): Unadjusted technique survival by age (censored for death and transplant), 2004-2013 Source: 21st MDTR Report 2013, NRR

  24. Figure 12.3.2(b): Unadjusted technique survival by age (censored for death and transplant), 2004-2013 Kaplan-Meier survival estimates, by Age 1.00 0.80 Age>=65 0.60 Age 55-64 Age 1-14 Cumulative survival Age 35-44 Age 45-54 0.40 Age 15-24 Age 25-34 0.20 0.00 0 12 24 36 48 60 72 84 96 108 120 132 144 Duration in months Source: 21st MDTR Report 2013, NRR

  25. Table 12.3.3(a): Unadjusted technique survival by gender (uncensored for death and transplant), 2004-2013 Source: 21st MDTR Report 2013, NRR

  26. Figure 12.3.3(a): Unadjusted technique survival by gender (uncensored for death and transplant), 2004-2013 Kaplan-Meier survival estimates, by sex 1.00 0.75 Cumulative survival 0.50 Female 0.25 Male 0.00 0 12 24 36 48 60 72 84 96 108 120 Duration in months Source: 21st MDTR Report 2013, NRR

  27. Table 12.3.3(b): Unadjusted technique survival by gender (censored for death and transplant), 2004-2013 Source: 21st MDTR Report 2013, NRR

  28. Figure 12.3.3(b): Unadjusted technique survival by gender (censored for death and transplant), 2004-2013 Kaplan-Meier survival estimates, by sex 1.00 0.75 Female Cumulative survival 0.50 Male 0.25 0.00 0 12 24 36 48 60 72 84 96 108 120 Duration in months Source: 21st MDTR Report 2013, NRR

  29. Table 12.3.4(a): Unadjusted technique survival by diabetes status (uncensored for death and transplant), 2004-2013 Source: 21st MDTR Report 2013, NRR

  30. Figure 12.3.4(a): Unadjusted technique survival by Diabetes status (uncensored for death and transplant), 2004-2013 Kaplan-Meier survival estimates, by Diabetes 1.00 0.75 Cumulative survival 0.50 0.25 Non-diabetic Diabetic 0.00 0 12 24 36 48 60 72 84 96 108 120 132 144 Duration in months Source: 21st MDTR Report 2013, NRR

  31. Table 12.3.4(b): Unadjusted technique survival by diabetes status (censored for death and transplant), 2004-2013 Source: 21st MDTR Report 2013, NRR

  32. Figure 12.3.4(b): Unadjusted technique survival by diabetes status (censored for death and transplant), 2004-2013 Kaplan-Meier survival estimates, by Diabetes 1.00 0.75 Diabetic Cumulative survival 0.50 Non-diabetic 0.25 0.00 0 12 24 36 48 60 72 84 96 108 120 Duration in months Source: 21st MDTR Report 2013, NRR

  33. Table 12.3.5: Unadjusted technique survival by Kt/V, 2004-2013 Source: 21st MDTR Report 2013, NRR

  34. Figure 12.3.5: Unadjusted technique survival by Kt/V, 2004-2013 Kaplan-Meier survival estimates, by KTV 1.00 0.75 Cumulative survival 0.50 Kt/V >2.0 0.25 Kt/V 1.7-2.0 Kt/V <1.7 0.00 0 24 48 72 96 120 144 168 Duration in months Source: 21st MDTR Report 2013, NRR

  35. Table 12.3.6: Adjusted hazard ratio for change of modality, 2004-2013 Source: 21st MDTR Report 2013, NRR

  36. Table 12.3.7(a): Reasons for drop-out from PD program, 2004-2013 Source: 21st MDTR Report 2013, NRR

  37. Figure 12.3.7(a): Reasons for drop-out from PD program, 2004-2013 Death Transplant Peritonitis Catheter related infection Membrane failure Technical problem Patient preference Others Unknown 100 80 60 Percent (%) 40 20 0 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Source: 21st MDTR Report 2013, NRR

  38. Table 12.3.7(b): Drop-out rate from PD program with time on treatment, 2004-2013 Source: 21st MDTR Report 2013, NRR

  39. Table 12.3.8: Time on PD (2004-2013) Source: 21st MDTR Report 2013, NRR

  40. Table 12.4.1: Variation of peritonitis rate (pt-month/epi) among PD centres, 2004-2013 Source: 21st MDTR Report 2013, NRR

  41. Figure 12.4.1: Variation in peritonitis rate among PD centres, 2013 Peritonitis rate (lower 95% CI, upper 95% CI) 300 250 200 Rate, pt-month/epi 150 100 50 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 Centre Source: 21st MDTR Report 2013, NRR

  42. Table 12.4.2(a): Causative organism in PD peritonitis, 2004-2013 Source: 21st MDTR Report 2013, NRR

  43. Figure12.4.2(b): Causative organism in PD peritonitis, 2004-2013 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 0 100 200 300 400 500 Frequency Staph. Aureus Staph Coagulase Neg. Other Gram positive Pseudomonas E.Coli Polymicrobial Fungal Mycobacterium Culture Negative Source: 21st MDTR Report 2013, NRR

  44. Table 12.4.3(b): Outcome of peritonitis by causative organism, 2009-2013 Source: 21st MDTR Report 2013, NRR

  45. Figure 12.4.3(b): Outcome of peritonitis by causative organism, 2009-2013 Resolved Not resolved, catheter removed Death 100 80 60 Percent (%) 40 20 0 E.Coli Strep Others Fungal Others Others Klebsiella Enterobacter No growth Polymicrobial Acinetobacter Staph. Aureus Pseudomonas Mycobacterium Staph Coagulase Neg. Year Source: 21st MDTR Report 2013, NRR

  46. Figure 12.4.3(c): Outcome of peritonitis by causative organism by era, 2004-2008 & 2009-2013 Resolved Not resolved, catheter removed Death 100 80 60 Percent (%) 40 20 0 2004-08 2009-13 2004-08 2009-13 2004-08 2009-13 2004-08 2009-13 2004-08 2009-13 2004-08 2009-13 2004-08 2009-13 2004-08 2009-13 2004-08 2009-13 2004-08 2009-13 2004-08 2009-13 2004-08 2009-13 2004-08 2009-13 2004-08 2009-13 2004-08 2009-13 Strep E.Coli Others Others Others Fungal Klebsiella No growth Polymicrobial Enterobacter Acinetobacter Staph. Aureus Pseudomonas Mycobacterium Staph Coagulase Neg. Source: 21st MDTR Report 2013, NRR

  47. Table 12.4.4: Risk factors influencing peritonitis rate, 2004-2013 Source: 21st MDTR Report 2013, NRR

More Related